Literature DB >> 18311498

Functional outcome after redo below-knee amputation.

Chad N Stasik1, Scott A Berceli, Peter R Nelson, W Anthony Lee, C Keith Ozaki.   

Abstract

BACKGROUND: Nonhealing below-knee amputation (BKA) necessitates redo BKA or conversion to above-knee amputation (AKA). Outcomes after redo BKA remain poorly defined. We hypothesized that in selected patients redo BKA results in favorable functional outcomes.
METHODS: Patients undergoing redo BKA at a single institution during 4 years were reviewed. A concurrent cohort proceeding directly to ipsilateral AKA served as comparative controls.
RESULTS: Of 138 BKAs, 23 (17%) failed to heal primarily. Baseline demographics and medical comorbidities were similar between groups. Clinicians selected 14 for redo BKA and 9 for ipsilateral AKA. Eight (57%) of those undergoing redo BKA had a history of minor stump trauma and 13 (93%) had a palpable popliteal pulse, compared with no trauma (P = 0.007) and 4 (44%, P = 0.018) palpable popliteal pulses in the AKA group. Functionally, 86% of redo-BKA patients returned home, all eventually healed, and 86% walked, whereas none in the AKA group walked.
CONCLUSIONS: In selected patients, redo BKA yields excellent functional outcomes. A history of minor stump trauma and a palpable popliteal pulse favor redo BKA compared with conversion to AKA.

Entities:  

Mesh:

Year:  2008        PMID: 18311498     DOI: 10.1007/s00268-008-9500-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  15 in total

1.  Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers.

Authors:  S A Berceli; A K Chan; F B Pomposelli; G W Gibbons; D R Campbell; C M Akbari; D T Brophy; F W LoGerfo
Journal:  J Vasc Surg       Date:  1999-09       Impact factor: 4.268

2.  Major lower extremity amputations at a Veterans Affairs hospital.

Authors:  Carlos P Cruz; John F Eidt; Christy Capps; Leah Kirtley; Mohammed M Moursi
Journal:  Am J Surg       Date:  2003-11       Impact factor: 2.565

Review 3.  Modified supracondylar amputation of the femur.

Authors:  James Majeski
Journal:  Am Surg       Date:  2004-03       Impact factor: 0.688

4.  Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity.

Authors:  Gregorio Brevetti; Vittorio Schiano; Giusy Sirico; Giuseppe Giugliano; Eugenio Laurenzano; Massimo Chiariello
Journal:  J Vasc Surg       Date:  2006-06-06       Impact factor: 4.268

Review 5.  An update on endovascular therapy of the lower extremities.

Authors:  Mark C Bates; Ali F Aburahma
Journal:  J Endovasc Ther       Date:  2004-12       Impact factor: 3.487

6.  Amputations below the knee.

Authors:  E M Burgess; J H Zettl
Journal:  Artif Limbs       Date:  1969

Review 7.  Optimal medical management of peripheral arterial disease.

Authors:  Terry W Rice; Alan B Lumsden
Journal:  Vasc Endovascular Surg       Date:  2006 Aug-Sep       Impact factor: 1.089

8.  Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients.

Authors:  Spence M Taylor; Corey A Kalbaugh; Dawn W Blackhurst; Steven E Hamontree; David L Cull; Hayley S Messich; R Todd Robertson; Eugene M Langan; John W York; Christopher G Carsten; Bruce A Snyder; Mark R Jackson; Jerry R Youkey
Journal:  J Vasc Surg       Date:  2005-08       Impact factor: 4.268

9.  Functional outcome in a contemporary series of major lower extremity amputations.

Authors:  Mark R Nehler; Joseph R Coll; William R Hiatt; Judith G Regensteiner; Gabriel T Schnickel; William A Klenke; Pam K Strecker; Michelle W Anderson; Darrell N Jones; Thomas A Whitehill; Shevie Moskowitz; William C Krupski
Journal:  J Vasc Surg       Date:  2003-07       Impact factor: 4.268

Review 10.  Vascular disease of the lower extremities in diabetes mellitus.

Authors:  F W LoGerfo; G W Gibbons
Journal:  Endocrinol Metab Clin North Am       Date:  1996-06       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.